Penumbra (NYSE:PEN) announced its earnings results on Thursday. The company reported $0.25 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.18 by $0.07, Briefing.com reports. Penumbra had a net margin of 3.03% and a return on equity of 6.80%. The business had revenue of $139.50 million for the quarter, compared to the consensus estimate of $133.98 million. During the same quarter in the prior year, the firm posted $0.17 earnings per share. The business’s revenue for the quarter was up 24.8% on a year-over-year basis.
PEN stock traded down $8.19 during trading on Friday, hitting $164.74. The company had a trading volume of 1,524,751 shares, compared to its average volume of 452,991. The firm has a market capitalization of $5.71 billion, a P/E ratio of 323.02, a PEG ratio of 9.46 and a beta of 0.73. Penumbra has a 52-week low of $110.84 and a 52-week high of $185.70. The company has a 50 day simple moving average of $148.54 and a 200-day simple moving average of $150.86. The company has a quick ratio of 4.33, a current ratio of 6.23 and a debt-to-equity ratio of 0.10.
PEN has been the topic of several recent analyst reports. ValuEngine downgraded shares of Penumbra from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research downgraded shares of Penumbra from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. Wells Fargo & Co raised their price target on shares of Penumbra from $185.00 to $195.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, Royal Bank of Canada set a $174.00 price target on shares of Penumbra and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $174.50.
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Featured Story: Does the Dogs of the Dow strategy work?
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.